• Exchange: Berlin
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

Akebia Therapeutics Inc

+ Add to Watchlist

AX9:GR

9.708 EUR 0.351 3.75%

As of 13:35:21 ET on 12/19/2014.

Snapshot for Akebia Therapeutics Inc (AX9)

Open: 9.678 Day's Range: 9.591 - 9.928 Volume: 137
Previous Close: 9.357 52wk Range: 7.109 - 21.360 1-Yr Rtn: -

Stock Chart for AX9

No chart data available.
  • AX9:GR 9.724
  • 1D
  • 1M
  • 1Y
9.357
Interactive AX9 Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for AX9

Current P/E Ratio (ttm) -
Estimated P/E(12/2014) -
Relative P/E vs. DAX -
Earnings Per Share (USD) (ttm) -
Est. EPS (USD) (12/2014) -6.9900
Est. PEG Ratio -
Market Cap (M EUR) 197.47
Shares Outstanding (M) 20.34
30 Day Average Volume 93
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 02/21/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for AX9

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for AX9

Akebia Therapeutics, Inc. manufactures biopharmaceutical products. The Company develop and distributes novel therapeutics based on the biology of hypoxia inducible factor (HIF) for patients with kidney diseases. Akebia Therapeutics serves customers in the United States.

John P ButlerPresident/CEOJason A AmelloSenior VP/CFO/Treasurer
Brad MaroniSenior VP/Chief Medical OfficerNicole R Hadas "Nikki"VP/General Counsel
More Company Profile & Key Executives for AX9

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil